Product Pipeline
Our MELACINE® melanoma vaccine is available for sale in Canada. MELACINE vaccine consists of lysed (broken) cells from two human melanoma cell lines combined with our proprietary ENHANZYN™ adjuvant. ENHANZYN adjuvant includes MPL® and mycobacterial cell wall skeleton, both of which activate the human immune system in the context of vaccination. We are in discussions with the FDA regarding the future regulatory path of MELACINE.

Related News
02/28/2002 ODAC endorses Phase III trial design for Melacine melanoma vaccine
01/15/2002 Corixa to present Melacine data and Phase III trial design to ODAC
02/15/2001 Melacine available in Canada
A business overview as well as information on Corixa's partners, management team, employment opportunities, and company contacts.
Corixa's near-term products and adjuvant for research applications.
Product pipeline, therapeutic areas of focus, products, technology platforms, and publications.
Company reports, stockholder letter, events calendar, stock quote, analyst list, and materials request.
Current and archived company press releases.
Product pipeline, therapeutic areas of focus, products, technology platforms, and publications.